Around the world -- and even right here in the United States -- there are diseases that cause tremendous human suffering and wreak havoc on the lives of millions. Together with our network of global partners, the Sabin Vaccine Institute works tirelessly to reduce the impact of vaccine preventable and neglected tropical diseases. Find out more about our three main programs:
The Global Network for Neglected Tropical Diseases works to raise awareness political will and funding necessary to control and eliminate the seven most common neglected tropical diseases (NTDs).
“Drug donations and research and development support from pharmaceutical companies are just the beginning of a comprehensive collaboration between the private sector, NGOs and country governments to meet our 2020 elimination targets."
-Dr. Neeraj Mistry, Managing Director, Global Network for Neglected Tropical Diseases
The Vaccine Advocacy and Education program at Sabin is dedicated to reducing the burden of preventable diseases by bringing together key stakeholders and leaders in government, private sector and civil society in order to foster cooperation, share information and best practices and develop improved vaccine policy and access.
"Immunization is certainly one of the most successful and cost-effective public health interventions, preventing 2 – 3 million deaths every year. Through increased vaccine advocacy, education and policy, Sabin, with its partners, strives to ensure that available vaccines reach every person in need. There are few interventions in public health that can save as many lives so quickly."
-Dr. Jon Andrus, Executive Vice-President, Sabin Vaccine Institute
Since 2000, our President, Dr. Peter Hotez, has led the Sabin Vaccine Institute Product Development Partnership’s (Sabin PDP) progress in developing vaccines for diseases of the world’s poorest people. More than a decade of work has resulted in a low-cost model that serves as a blueprint for developing vaccines that otherwise have no commercial market.
“We are filling a gap to produce a vaccine for underrepresented populations, where no traditional commercial market currently exists.”
-Dr. Peter Hotez, President, Sabin Vaccine Institute